BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
102 results:

  • 1. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid tumors.
    Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
    Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Predictive value of SIRI and SII for metastases in RCC: a prospective clinical study.
    Arı E; Köseoğlu H; Eroğlu T
    BMC Urol; 2024 Jan; 24(1):14. PubMed ID: 38218876
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative Analysis for Differentiating Hypovascular Solid Renal Lesions.
    Li J; Huang X; Wang L; Wang X; Li Y; Liu X; Ye N; Yang S; Nie F
    Ultrasound Med Biol; 2024 Feb; 50(2):295-303. PubMed ID: 37996360
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
    Minami K; Osawa T; Kojima T; Hara T; Eto M; Takeuchi A; Nakai Y; Ueda K; Ozawa M; Uemura M; Ohba K; Tamura K; Shindo T; Nakagomi H; Takahashi A; Anai S; Yokomizo A; Morizane S; Kimura T; Shimazui T; Miyauchi Y; Mitsuzuka K; Hara H; Yoshimura K; Shiina H; Ito YM; Murai S; Nishiyama H; Shinohara N; Kitamura H;
    Urol Oncol; 2023 Nov; 41(11):458.e9-458.e19. PubMed ID: 37798145
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
    Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
    BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition.
    Saliby RM; Saad E; Labaki C; Xu W; Braun DA; Viswanathan SR; Bakouny Z
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):1015-1026. PubMed ID: 37385938
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pseudoenhancement in Cystic Renal Lesions - Impact of Virtual Monoenergetic Images of Photon-Counting Detector CT on Lesion Classification.
    Schade KA; Mergen V; Sartoretti T; Alkadhi H; Euler A
    Acad Radiol; 2023 Sep; 30 Suppl 1():S305-S313. PubMed ID: 37150736
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Signatures of Co-Deregulated Genes and Their Transcriptional Regulators in kidney Cancers.
    Ioannou I; Chatziantoniou A; Drenios C; Christodoulou P; Kourti M; Zaravinos A
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047552
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges.
    Papavasileiou G; Tsilingiris D; Spyrou N; Vallianou NG; Karampela I; Magkos F; Dalamaga M
    Semin Cancer Biol; 2023 Jun; 91():70-98. PubMed ID: 36893965
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PCGF6/MAX/KDM5D facilitates MAZ/cdk4 axis expression and pRCC progression by hypomethylation of the DNA promoter.
    Zhu M; Zhang RN; Zhang H; Qu CB; Zhang XC; Ren LX; Yang Z; Gu JF
    Epigenetics Chromatin; 2023 Mar; 16(1):9. PubMed ID: 36890610
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of cdk4/6 Inhibitors.
    Huang Z; Li X; Tang B; Li H; Zhang J; Sun R; Ma J; Pan Y; Yan B; Zhou Y; Ding D; Yan Y; Jimenez R; Orme JJ; Jin X; Yang J; Huang H; Jia Z
    Cancer Res; 2023 Mar; 83(6):875-889. PubMed ID: 36637424
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway.
    Peng BY; Singh AK; Chan CH; Deng YH; Li PY; Su CW; Wu CY; Deng WP
    BMC Cancer; 2023 Jan; 23(1):1. PubMed ID: 36597025
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Trends of kidney cancer burden from 1990 to 2019 in European Union 15 + countries and World Health Organization regions.
    Jani C; Abdallah N; Mouchati C; Jani R; Sharma R; Bhatt P; Hanbury G; Salciccioli J; Singh H; Shalhoub J; McKay RR; Marshall DC
    Sci Rep; 2022 Dec; 12(1):22368. PubMed ID: 36572700
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Biochemical and clinical effects of RPS20 expression in renal clear cell carcinoma.
    Shen C; Chen Z; Zhang Y; Xu W; Peng R; Jiang J; Zuo W; Fan Y; Zheng B
    Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36484407
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Does the LHPP gene share a common biological function in pancancer progression?
    Guo K; Tian W; Wang H; Chang D; Dou Y; Yuan J; Chen Y; Hou B
    BMC Med Genomics; 2022 Nov; 15(1):239. PubMed ID: 36376886
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to cdk4/6 inhibitors.
    Liu W; Zhang B; Zhang D; Guo F; Ye K; Zhu L; Jin X
    Cell Death Dis; 2022 Apr; 13(4):295. PubMed ID: 35368029
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progression.
    Yan Y; Bao G; Pei J; Cao Y; Zhang C; Zhao P; Zhang Y; Damirin A
    Biochim Biophys Acta Mol Basis Dis; 2022 Jul; 1868(7):166401. PubMed ID: 35346818
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Therapeutic potential of cdk4/6 inhibitors in renal cell carcinoma.
    Sager RA; Backe SJ; Ahanin E; Smith G; Nsouli I; Woodford MR; Bratslavsky G; Bourboulia D; Mollapour M
    Nat Rev Urol; 2022 May; 19(5):305-320. PubMed ID: 35264774
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Decreased risk of COVID-19 pneumonia in children and adolescents during the Delta variant emergence.
    Murillo-Zamora E; Trujillo X; Huerta M; Ríos-Silva M; Baltazar-Rodríguez LM; Guzmán-Esquivel J; Benites-Godínez V; Ortega-Ramírez AD; Mendoza-Cano O
    Public Health; 2022 Mar; 204():9-11. PubMed ID: 35085915
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Molecular determinants of response to PD-L1 blockade across tumor types.
    Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
    Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.